Department of Pathology, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo, Japan ; Cancer Diagnosis Laboratory, Japan Science and Technology Agency Innovation Plaza Hokkaido, Japan Science and Technology Agency, Kita-Ku, Sapporo, Japan.
PLoS One. 2013 Nov 11;8(11):e69095. doi: 10.1371/journal.pone.0069095. eCollection 2013.
Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are defined as a small population of cancer cells that have self-renewal ability, differentiation ability and high tumor-initiating ability. CSCs/CICs are resistant to cancer therapies including chemotherapy and radiotherapy. Therefore, CSCs/CICs are thought to be responsible for cancer recurrence and distant metastasis after treatment. However, the molecular mechanisms of CSCs/CICs are still elusive. In this study, we isolated CSCs/CICs as side population (SP) cells from lung carcinoma, colon carcinoma and breast carcinoma cells and analyzed the molecular mechanisms of CSCs/CICs. cDNA micro-array screening and RT-PCR analysis revealed that sperm mitochondria-associated cysteine-rich protein (SMCP) is ectopically expressed in SP cells. 5'-Rapid amplification of cDNA end (RACE) analysis revealed that the SMCP transcript in SP cells was a variant form (termed vt2) which is composed from only one exon. SMCP vt2 was detected in only cancer cells, whereas the wild-type (vt1) form of SMCP was expressed in the testis. SMCP was shown to have a role in tumor initiation by SMCP overexpression and SMCP knockdown using siRNAs in lung cancer cells. Taken together, the initiation results indicate that an ectopically expressed variant form of SMCP has a role in tumor initiation of CSCs/CICs and that the variant form of SMCP might be a novel CSC/CIC marker and a potential and promising target of CSC/CIC-targeting therapy.
癌症干细胞样细胞(CSCs)/癌症起始细胞(CICs)被定义为具有自我更新能力、分化能力和高肿瘤起始能力的一小部分癌细胞。CSCs/CICs 对包括化疗和放疗在内的癌症治疗具有耐药性。因此,CSCs/CICs 被认为是治疗后癌症复发和远处转移的原因。然而,CSCs/CICs 的分子机制仍不清楚。在这项研究中,我们从肺癌、结肠癌和乳腺癌细胞中分离出 CSCs/CICs 作为侧群(SP)细胞,并分析了 CSCs/CICs 的分子机制。cDNA 微阵列筛选和 RT-PCR 分析显示,精子线粒体相关半胱氨酸丰富蛋白(SMCP)在 SP 细胞中异位表达。5'-快速扩增 cDNA 末端(RACE)分析显示,SP 细胞中的 SMCP 转录本是一种变体形式(称为 vt2),仅由一个外显子组成。SMCP vt2 仅在癌细胞中检测到,而 SMCP 的野生型(vt1)形式在睾丸中表达。SMCP 过表达和使用 siRNA 在肺癌细胞中敲低 SMCP 的实验表明,SMCP 在肿瘤起始中起作用。总之,这些起始实验结果表明,SMCP 的异位表达变体形式在 CSCs/CIC 的肿瘤起始中起作用,并且该变体形式的 SMCP 可能是一种新型的 CSC/CIC 标志物,也是 CSC/CIC 靶向治疗的潜在和有前途的靶点。